Guidelines for Antihypertensive Treatment
- 1 January 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 15 (1_suppl), S51-S54
- https://doi.org/10.1097/01.asn.0000093242.48333.3b
Abstract
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Study, the largest double-blind, randomized trial in hypertensive patients, confirmed and strengthened the clinical relevance of thiazide diuretics in the treatment of hypertension but did not prove the superiority of these drugs. Its claim of the superiority of chlorthalidone was based on some secondary outcomes, principally represented by (1) an increased incidence of stroke in the doxazosin and lisinopril arms, an effect that might be explained by differences in systolic BP; (2) greater morbidity but not mortality for congestive heart failure (CHF) in the doxazosin, amlodipine, and lisinopril arms, a finding that might reflect poor accuracy in the diagnosis and/or especially the switching from diuretic treatment in 90% of patients. Moreover, the ALLHAT study has other limitations, and its conclusions are in contrast with data from overall controlled clinical trials indicating that given the same BP reduction, the benefit of different drug classes is similar. As to whether the ALLHAT study will influence ongoing guidelines concerning the choice of antihypertensive drugs, the answer is “yes” if interpretation of its data in favor of diuretics and cost of drugs become the preponderant considerations, as it was in recent JNC VII guidelines. However, the more liberal approach based on the choice of all available drug classes seems still to be valid, as is in the ESH-ESC guidelines, if the preponderant consideration is that the real benefit of antihypertensive therapy is due to efficient BP control and not to a particular benefit of a single drug class.Keywords
This publication has 18 references indexed in Scilit:
- Cardiovascular prevention and blood pressure reductionJournal of Hypertension, 2003
- 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*Journal of Hypertension, 2003
- The Study on Cognition and Prognosis in the Elderly (SCOPE)Journal of Hypertension, 2003
- The ALLHAT studyJournal of Hypertension, 2003
- A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the ElderlyThe New England Journal of Medicine, 2003
- The meaning of ALLHATJournal of Hypertension, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Antihypertensive treatment in patients with type-2 diabetes mellitusJournal of Hypertension, 2002
- Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2000
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureArchives of Internal Medicine, 1997